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A t present a problem of dental diseases (periodontitis, stomatitis, gingivitis, etc.) and their treatment is the issue of importance for both Ukraine and the world in general [6, 7] . One of the main causes of these diseases are microorganisms, which inhabit the oral cavity and are activated in case of unhealthy diet, immunosuppressive conditions of the organism, periodontal injuries or as a consequence of infectious diseases, etc. That is why the treatment is aimed not only at suppressing inflammation and relieving pain, but also at these microorganisms themselves [8, 9, 11, 12] .
Some of commonly used medicines for treating periodontitis, stomatitis, and gingivitis are antimicrobial medicines of synthetic and natural (mostly phytogenic) origin [10, 13, [14] [15] [16] .
The aim of this paper is to conduct pharmacoeconomic analysis of antimicrobial medicines used in dentistry for treatment of periodontal diseases. In order to do this, it was necessary to examine antimicrobial properties of medicines, to develop the method of estimation of the complex indicator of the drug antimicrobial activity and to conduct pharmacoeconomic analysis on its basis.
Materials and Methods
For the purpose of screening of antimicrobial properties the following medicines were taken -the tincture of Sophora japonica, the tincture of eucalyptus, the tincture of propolis, the tincture of calendula, "Fitodent", "Stomatofit", "Rotokan", "Romazulan", "Sanguiritrin", "Chlorophillipt" ("Galichpharm" JSC), "Kamistad", "Chlorhexidine digluconate", "Orasept", "Hexoral" and "Metrogyl Denta".
The antimicrobial activity of medicines was determined by the method of "wells" easily performed [2] with determination of diameters of the microorganisms growth inhibition zones [1] curs by the normal law of distribution, calculation of an average arithmetic diameter and its measurement error were determined with the help of correction for small samples using the Student criterion with the confidence level of 0.95 and the number of degrees of freedom of 5.
In order to calculate the complex indicator of the drug antimicrobial activity the method of vector algebra was used.
Calculation of the complex indicator of the drug antimicrobial activity and its measurement error was performed using the following formulas: (1) and (2) where: А is the complex indicator of the drug antimicrobial activity, dimensionless value, (the indicator efficiency ranges are: 1.0-1.5 -the medicine has a weak antimicrobial activity; 1.5-2.5 -the medicine has a medium antimicrobial activity; more than 2.5 -the medicine has a strong antimicrobial activity); а 1 , а 2 , а 3 , а 4 , а 5 , а 6 are weighing coefficients of the microorganism strain significance in the disease, in order to simplify we have taken them as a unit, however, application data from research on prevalence degree of microorganisms in affected people can be used [15] ; The cost of the course of treatment has been calculated using data from the package inserts, assuming that the course of treatment can take an average of 10 ± 4 days [4] . The cost of medicines is given on average from data of Kharkov pharmacies as of September, 2013.
Results and Discussion
Data on numerical values of the complex indicator of the antimicrobial activity of medicines, as well as other economic indicators are summarized in Table. As it can be seen from Table, almost all medicines are within the range of weak to medium value of the complex indicator of the antimicrobial activity (between 1.0 and 2.5). It is also worth mentioning that some medicines can be left in significant amount during the course of treatment (for instance, "Metrogyl Denta", "Hexoral", "Chlorophillipt" and "Fitodent"); that is why it is possible to recommend manufacturers to reduce the pack volume.
For pharmacoeconomic analysis two main indicators characterizing a medicine have been taken from Table. They are its complex indicator of the antimicrobial activity (pharmacological constituent) and cost of the course of treatment in entire packs (economic constituent) in hryvnia (UAH). Aiming to ordering of pharmacoeconomic indicators of the medicines studied it has been suggested to take the ratio of the treatment course cost in entire packs and the complex indicator of the drug antimicrobial activity. This indicator shows the drug cost per unit of the complex indicator of the drug antimicrobial activity while using. From the consumer's viewpoint, the lower this ratio is, the more beneficial it is for him. Therefore, in Fig. 1 below this indicator is presented in decreasing order for medicines under research.
As it can be seen from Fig. 1 , all medicines under research can be divided approximately into 4 groups. For the purpose of more visual presentation of drug distribution according to their complex indicator of the antimicrobial activity (which measurement error is taken at the level of 5%) and cost of the course of treatment (which measurement error is taken at the level of 50%) the data from Table is shown in Fig. 2 .
As it can be seen from Fig. 2 , the medicines under research are easily categorized into 5 main groups. The following medicines fall into the group of the best indicators (the maximum value of the complex indicator of the antimicrobial activity with the minimum cost of the course of treatment among the medicines studied): the tincture of Sophora japonica and chlorhexidine digluconate, although their values of the complex indicator of the antimicrobial activity are in the zone of the medium activity. Then, there is a group of new galenical medicines -"Sangviritrin" and "Chlorophillipt" (Galichpharm), which are slightly inferior in their antimicrobial activity and require increased expenditures on treatment on the part of the consumer.
They are followed by medicines from the third group -"Metrogyl Denta" and the tincture of eucalyptus, which demonstrate antimicrobial properties of the medium potency with acceptable cost for the course of treatment.
The forth group of medicines -"Rotokan", "Romazulan", the tincture of propolis and the tincture of calendula -have satisfactory antimicrobial properties with the acceptable cost for the course of treatment.
Finally, medicines of the fifth group -"Stomatofit", "Hexoral", "Orasept", "Kamistad" and "Fitodent" -appeared to be the most expensive and poorly efficient. CONCLUSIONS In this paper the pharmacoeconomic analysis of 15 antimicrobial medicines used in dentistry has been conducted. For this purpose the valuation method of antimicrobial properties of medicines on the basis of vector algebra has been suggested and applied; it allowed calculating a complex indicator of the drug antimicrobial activity for quantitative estimation of the pharmacological effect.
It has been shown that the tincture of Sophora japonica and the solution of chlorhexidine digluconate have the best indicators of antimicrobial properties and the lowest treatment cost among the medicines studied at the level of 5-10 UAH. The second group of medicines -"Sanguiritrin" and "Chlorophillipt" (Galychpharm) -is as good as the first one in terms of antimicrobial properties, but the course of treatment with these medicines costs up to 30-40 UAH. The third group of medicines -"Metrogyl Denta", the tincture of eucalyptus -exhibits antimicrobial properties of a medium potency and their cost for the treatment course is in the range of 10-20 UAH. The forth group of medicines -"Rotokan", "Romazulan", the tincture of calendula and the tincture of propolis -exhibits the weak antimicrobial properties and has a relatively low cost of treatment in the range of 5-20 UAH. The fifth group of medicines -"Stomatofit", "Orasept", "Hexoral", "Fitodent", and "Kamistad" -exhibits the weakest antimicrobial properties and has the most expensive course of treatment in the range of 40-80 UAH.
It has been noted that some of the medicines studied (for instance, "Metrogyl Denta", "Hexoral", "Chlorophillipt" and "Fitodent") have impractical volume since up to half of the pack is left after finishing the course of treatment. Therefore, we can recommend manufacturers to reduce the drug quantity in the pack by 30-50% for consumer's convenience. 
